J. Olijhoek

发表

Serum uric acid levels and risk for vascular diseases in patients with metabolic syndrome.

A. Algra, J. Jacobs, Y. van der Graaf, 2007, The Journal of rheumatology.

The relation between body iron stores and adipose tissue function in patients with manifest vascular disease

A. Koppen, E. Kalkhoven, F. Visseren, 2013, European journal of clinical investigation.

Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm.

Y. van der Graaf, F. Visseren, J. Olijhoek, 2007, European heart journal.

Low plasma levels of adiponectin are associated with low risk for future cardiovascular events in patients with clinical evident vascular disease.

Y. van der Graaf, F. Visseren, J. Olijhoek, 2007, American heart journal.

Defining the metabolic syndrome: Resolving unresolved issues?

Y. van der Graaf, F. Visseren, S. Haffner, 2007, European journal of internal medicine.

Presence of the metabolic syndrome does not impair coronary collateral vessel formation in patients with documented coronary artery disease.

D. Grobbee, Y. van der Graaf, M. Verhaar, 2005, Diabetes care.

Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm.

A. Algra, T. Rabelink, Y. van der Graaf, 2004, Atherosclerosis.

The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm.

A. Algra, T. Rabelink, Y. van der Graaf, 2004, European heart journal.

The metabolic syndrome: metabolic changes with vascular consequences

F. Visseren, J. Olijhoek, A. Wassink, 2007, European journal of clinical investigation.

Endothelial progenitor cell levels in obese men with the metabolic syndrome and the effect of simvastatin monotherapy vs. simvastatin/ezetimibe combination therapy.

S. Rafii, P. Doevendans, M. Verhaar, 2008, European heart journal.

Severe asymptomatic rhabdomyolysis complicating a mycoplasma pneumonia

J. Olijhoek, T. Wierema, Alex Gosselt, 2017, BMJ Case Reports.

Oral glucose tolerance test or metabolic syndrome criteria to predict risk in patients with coronary heart disease?

F. Visseren, J. Banga, P. Doevendans, 2005, European heart journal.

Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation.

P. Blankestijn, M. Hijmering, T. Rabelink, 2002, Journal of the American College of Cardiology.

The Effects of Low-Dose Simvastatin and Ezetimibe Compared to High-Dose Simvastatin Alone on Post-Fat Load Endothelial Function in Patients With Metabolic Syndrome: A Randomized Double-Blind Crossover Trial

F. Visseren, G. Dallinga-Thie, J. Olijhoek, 2008, Journal of cardiovascular pharmacology.

Carotid arterial stiffness is marginally higher in the metabolic syndrome and markedly higher in type 2 diabetes mellitus in patients with manifestations of arterial disease.

Y. van der Graaf, F. Visseren, J. Olijhoek, 2008, Atherosclerosis.

Levels of homocysteine are increased in metabolic syndrome patients but are not associated with an increased cardiovascular risk, in contrast to patients without the metabolic syndrome

Y. van der Graaf, M. Verhaar, F. Visseren, 2005, Heart.

The course of vascular risk factors and the occurrence of vascular events in patients with symptomatic peripheral arterial disease.

Y. van der Graaf, F. Visseren, J. Olijhoek, 2007, Journal of vascular surgery.

Multidisciplinary Vascular Screening Program Modestly Improves the Medical Treatment of Vascular Risk Factors

F. Visseren, B. Eikelboom, J. Olijhoek, 2005, Cardiovascular Drugs and Therapy.

Lipid‐lowering therapy does not affect the postprandial drop in high density lipoprotein‐cholesterol (HDL‐c) plasma levels in obese men with metabolic syndrome: a randomized double blind crossover trial

F. Visseren, G. Dallinga-Thie, J. Olijhoek, 2008, Clinical endocrinology.

Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm.

Y. van der Graaf, F. Visseren, J. Olijhoek, 2007, European heart journal.

Lipid‐lowering therapy does not affect the postprandial drop in high density lipoprotein‐cholesterol (HDL‐c) plasma levels in obese men with metabolic syndrome: a randomized double blind crossover trial

F. Visseren, G. Dallinga-Thie, J. Olijhoek, 2008, Clinical endocrinology.